navtemadlin
kartos therapeutics
['navtemadlin']
important update on the navtemadlin single agent phase 2 trial in r/r mf eloquently presented by at #eha23: impressive survival data and look forward to the readout of #boreas! #eha23 #sergeverstovsek 
Associate Professor, Leukemia at MD Anderson; myeloproliferative neoplasm expert, NCCN panelist. Tweets reflect my own views; not necessarily my institution's.